Backgroundβ-Alanine (βA) has been shown to improve performance during cycling. This study was the first to examine the effects of βA supplementation on the onset of blood lactate accumulation (OBLA) during incremental treadmill running.MethodsSeventeen recreationally-active men (mean ± SE 24.9 ± 4.7 yrs, 180.6 ± 8.9 cm, 79.25 ± 9.0 kg) participated in this randomized, double-blind, placebo-controlled pre/post test 2-treatment experimental design. Subjects participated in two incremental treadmill tests before and after 28 days of supplementation with either βA (6.0 g·d-1)(βA, n = 8) or an equivalent dose of Maltodextrin as the Placebo (PL, n = 9). Heart rate, percent heart rate maximum (%HRmax), %VO2max@OBLA (4.0 mmol.L-1 blood lactate concentration) and VO2max (L.min-1) were determined for each treadmill test. Friedman test was used to determine within group differences; and Mann-Whitney was used to determine between group differences for pre and post values (p < 0.05).ResultsThe βA group experienced a significant rightward shift in HR@OBLA beats.min-1 (p < 0.01) pre/post (161.6 ± 19.2 to 173.6 ± 9.9) but remained unchanged in the PL group (166.8 ± 15.8 to 169.6 ± 16.1). The %HRmax@OBLA increased (p < 0.05) pre/post in the βA group (83.0% ± 9.7 to 88.6% ± 3.7) versus no change in the PL group (86.3 ± % 4.8 to 87.9% ± 7.2). The %VO2max@OBLA increased (p < 0.05) in the βA group pre/post (69.1 ± 11.0 to 75.6 ± 10.7) but remained unchanged in the PL group (73.3 ± 7.3 to 74.3 ± 7.3). VO2max (L.min-1) decreased (p < 0.01) in the βA group pre/post (4.57 ± 0.8 to 4.31 ± 0.8) versus no change in the PL group (4.04 ± 0.7 to 4.18 ± 0.8). Body mass kg increased (p < 0.05) in the βA group pre/post (77.9 ± 9.0 to 78.3 ± 9.3) while the PL group was unchanged (80.6 ± 9.1 to 80.4 ± 9.0).ConclusionsβA supplementation for 28 days enhanced sub-maximal endurance performance by delaying OBLA. However, βA supplemented individuals had a reduced aerobic capacity as evidenced by the decrease in VO2max values post supplementation.

No abstract

Currently, there are no set standards or quantitative guidelines available in the U.S. for arsenic levels in rice cereal, one of the most common first solid foods for infants. The objective of this study was to evaluate whether the detected levels of inorganic arsenic (Asi) in rice cereal in the U.S. market are safe for consumption by infants and toddlers. A risk assessment was conducted based on literature reviews of the reported Asi in rice cereal from the U.S. Food and Drug Administration’s (FDA) survey and the recommended daily intake of rice cereal by body weight, for infants and toddlers between four and 24 months old. As a part of risk management, a maximum contaminant level (MCL) for Asi in rice cereal was computed considering overall exposure sources including drinking water, infant formula, and other infant solid foods. Hazard quotients (HQs) for acute and chronic exposures were calculated based on the U.S. Agency for Toxic Substances and Disease Registry’s (ATSDR) Minimal Risk Level (MRL)acute (5.0 × 10−3 mg/kg/day) and MRLchronic (3.0 × 10−4 mg/kg/day). A cancer slope or potency factor of 1.5 mg/kg/day was used to predict an incremental lifetime cancer risk (ILCR). Exposure assessment showed that the largest source of Asi for infants and toddlers between four and 24 months old was rice cereal (55%), followed by other infant solid food (19%), and drinking water (18%). Infant formula was the smallest source of Asi for babies (9%) at the 50th percentile based on Monte Carlo simulations. While HQacute were consistently below 1.0, HQchronic at the 50 and 75th percentiles exceeded 1.0 for both rice cereal and total sources. ILCR ranged from 10−6 (50th) to 10−5 (75th percentile). MCLs for Asi in rice cereal ranged from 0.0 (chronic) to 0.4 mg/kg (acute exposures).

No abstract

No abstract